<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908466</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00028588</org_study_id>
    <nct_id>NCT00908466</nct_id>
  </id_info>
  <brief_title>Sirolimus as Therapeutic Approach to Uveitis</brief_title>
  <acronym>SAVE</acronym>
  <official_title>A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MacuSight, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out about the safety and effectiveness of the study
      drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of
      sirolimus, and yet to avoid the potential complications of systemic use of the drug. In this
      study, the investigators will administer sirolimus either around (subconjunctival injection)
      or inside the eye (intravitreal injection). Local administration of sirolimus to the eye is
      not expected to have effects on the rest of the body. Therefore, it may offer a safer way
      than the current methods used to control the inflammation caused by non-infectious uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveitis is a condition in which certain parts of your eye become inflamed. The inflammation
      is usually recurrent. If the inflammation is not treated adequately, permanent damage to the
      eye and to the vision may occur. The inflammation can be caused by infectious or non
      infectious causes. The current research is being done to determine the safety and the
      usefulness of treatment of non-infectious uveitis using a drug called sirolimus.

      Current treatment options for uveitis include oral corticosteroids and drugs that weaken the
      immune system of the body (i.e., immunosuppressant drugs). Treatment using oral
      corticosteroids, especially for long periods, may cause many undesirable side effects and
      complications such as high blood sugar, high blood pressure, bone weakness, obesity, stomach
      ulcers, abnormal hair growth, and increased risks of infection. In addition to that, in some
      cases, the disease cannot be controlled even with the highest dose of steroids.

      Injection of steroids around and inside the eye can be used to control uveitis. However, the
      inflammation does not always respond to such kind of treatment. The eyes may develop high
      pressure and cataract with injections of steroids into the eyes or around the eyes.

      On the other hand, despite their potential effectiveness, treatment with drugs that weaken
      the immune system may cause severe side effects. Increased risk of infection is a common side
      effect of all the immunosuppressant drugs. The immune system protects the body from
      infections. When the immune system is suppressed, infections are more likely to happen. Some
      of these infections are potentially dangerous. Because the immune system protects the body
      against some forms of cancer, immunosuppressant drugs are also associated with a slightly
      increased risk of cancer. For example, long-term use of immunosuppressant drugs may carry an
      increased risk of developing skin cancer as a result of the combination of the drugs and
      exposure to sunlight. The immunosuppressive drugs are very powerful and can cause serious
      side effects such as high blood pressure, kidney problems, and liver problems. Some side
      effects may not show up until years after the medicine is used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH)</measure>
    <time_frame>6 months</time_frame>
    <description>Vitreous Haze is calculated using a 9 step photographic haze in uveitis patients using fundus photograph</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline VA by ETDRS</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Uveitis</condition>
  <condition>Intermediate Uveitis</condition>
  <condition>Posterior Uveitis</condition>
  <condition>Panuveitis</condition>
  <arm_group>
    <arm_group_label>Intravitreal Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subconjunctival Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (rapamycin)</intervention_name>
    <description>Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.</description>
    <arm_group_label>Intravitreal Injection</arm_group_label>
    <other_name>Rapamycin, Rapamune, Sirolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (rapamycin)</intervention_name>
    <description>Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.</description>
    <arm_group_label>Subconjunctival Injection</arm_group_label>
    <other_name>Rapamycin, Rapamune, Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females greater than or equal to 18 years of age;

          2. Able to give informed consent and attend all study visits;

          3. Have diagnosis of uveitis determined by the Investigator to be non infectious;

               -  Have active uveitis, defined as having at least 1+ Vitreous Haze and/or at least
                  1+ Vitreous Cell Count (SUN scale), and:

                    -  are receiving no other treatment; or,

                    -  are receiving prednisone ≥10 mg/day (or equivalent dose of another
                       corticosteroid) and/or at least 1 other systemic immunosuppressant; or, b.
                       Have inactive disease, defined as having 0.5+ Vitreous Haze or less and a
                       grade of 0.5+ Vitreous Cell Count or less (SUN scale), and:

                    -  are receiving prednisone &lt;10 mg/day (or equivalent dose of another
                       corticosteroid) and/or at least 1 other systemic immunosuppressant.

          4. Have posterior, intermediate, or panuveitis; for panuveitis, if an anterior component
             is present, it must be less than the posterior component;

          5. Sufficient inflammation to require systemic treatment and, based on the Investigator's
             decision, warrants intravitreal or subconjunctival treatment;

          6. Best-corrected (ETDRS) visual acuity of 20/40 to 20/400 (approximately 70 to 20
             letters) in the study eye;

          7. Best- corrected ETDRS visual acuity of 20/400 or better in the fellow eye
             (approximately 20 letters).

        Exclusion Criteria:

          1. Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy
             (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate
             mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids
             for the treatment of the uveitis, and the uveitis in the fellow eyes, in the opinion
             of the investigator, cannot be controlled with standard local therapies alone;

          2. Any significant ocular disease that could compromise vision in the study eye. These
             include, but are not limited to:

               -  Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or
                  non-proliferative diabetic retinopathy (NPDR) that compromise the vision.

               -  Age-related macular degeneration;

               -  Myopic degeneration with active subfoveal choroidal neovascularization.

          3. Any of the following treatments within 90 days prior to Day 0 or anticipated use of
             any of the following treatments to the study eye:

               -  Intravitreal injections (including but not limited to steroids or anti-vascular
                  endothelial growth factors);

               -  Posterior subtenon's steroids.

          4. Intraocular surgery within 90 days prior to Day 0 in the study eye;

          5. Capsulotomy within 30 days prior to Day 0 in the study eye;

          6. If the patient has had glaucoma surgery (trabeculectomy or aqueous shunt device),
             there must be adequate conjunctiva

          7. History of vitreoretinal surgery or scleral buckling

          8. Any ocular surgery (including cataract extraction or capsulotomy) of the study eye
             anticipated within the first 180 days following Day 0;

          9. Intraocular pressure ≥25 mmHg in the study eye (glaucoma patients maintained on no
             more than 2 topical medications with intraocular pressure (IOP) &lt;25 mmHg are allowed
             to participate);

         10. Pupillary dilation inadequate for quality stereoscopic fundus photography in the study
             eye;

         11. Media opacity that would limit clinical visualization;

         12. Presence of any form of ocular malignancy in the study eye, including choroidal
             melanoma;

         13. History of herpetic infection in the study eye or adnexa;

         14. Presence of known active or inactive toxoplasmosis in either eye;

         15. Ocular or periocular infection in either eye;

         16. Participation in other investigational drug or device clinical trials within 30 days
             prior to Day 0, or planning to participate in other investigational drug or device
             clinical trials within 180 days following Day 0. This includes both ocular and
             non-ocular clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quan D Nguyen, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <results_first_submitted>August 24, 2016</results_first_submitted>
  <results_first_submitted_qc>December 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2018</results_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-infectious</keyword>
  <keyword>Uveitis</keyword>
  <keyword>Panuveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Panuveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravitreal Injection</title>
          <description>Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.</description>
        </group>
        <group group_id="P2">
          <title>Subconjunctival Injection</title>
          <description>Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravitreal Injection</title>
          <description>Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.</description>
        </group>
        <group group_id="B2">
          <title>Subconjunctival Injection</title>
          <description>Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="19.8"/>
                    <measurement group_id="B2" value="48" spread="18.2"/>
                    <measurement group_id="B3" value="47" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH)</title>
        <description>Vitreous Haze is calculated using a 9 step photographic haze in uveitis patients using fundus photograph</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Injection</title>
            <description>Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.</description>
          </group>
          <group group_id="O2">
            <title>Subconjunctival Injection</title>
            <description>Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH)</title>
          <description>Vitreous Haze is calculated using a 9 step photographic haze in uveitis patients using fundus photograph</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline VA by ETDRS</title>
        <time_frame>6 and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intravitreal Injection</title>
          <description>Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.</description>
        </group>
        <group group_id="E2">
          <title>Subconjunctival Injection</title>
          <description>Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Adverse Events</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Ocular Adverse Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Adverse Events</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation at the injection site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Quan Dong Nguyen, MD, MSc</name_or_title>
      <organization>University of Nebraska</organization>
      <phone>4025591855</phone>
      <email>quan.nguyen@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

